NantKwest (IBRX): Long-Term Debt to Capital Ratio

ImmunityBio, Inc. (IBRX) is developing a universal platform for creating anti-tumor vaccines, which simplifies the adaptation of therapy for various types of cancer. The company integrates ESG principles into its laboratory processes and strictly adheres to bioethical standards. However, challenges with mass production of drugs and reliance on founder funding create financial risks, with the indicator standing at 0.00. The linear price action on the chart below illustrates the market quotes for the asset.

To objectively assess the issuer's financial stability, a portfolio manager must analyze the long-term debt-to-equity ratio. The dynamics of long-term debt relative to equity reflect the extent of the company's reliance on borrowed funds with maturities exceeding one year, which is critical for ImmunityBio, Inc. (IBRX) when financing global cancer therapy developments amidst minimal geopolitical risks.